EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy - Wikidata - awgldk - TriplyDB

EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

http://www.wikidata.org/entity/Q36103054

about

Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Oral epithelial stem cells - implications in normal development and cancer metastasis.A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancer Grape seed extract and resveratrol prevent 4-nitroquinoline 1-oxide induced oral tumorigenesis in mice by modulating AMPK activation and associated biological responses Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.Models for Predicting Stage in Head and Neck Squamous Cell Carcinoma Using Proteomic and Transcriptomic Data.PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.An Ultra-Deep Targeted Sequencing Gene Panel Improves the Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma.Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure.Dysregulation of splicing proteins in head and neck squamous cell carcinoma.PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways.The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib.Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications.mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis.Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?Grandinin down-regulates phosphorylation of epidermal growth factor receptor.Down-regulation of Akt by methanol extracts of Impatiens balsamina L. promotes apoptosis in human oral squamous cell carcinoma cell lines.The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.Activation of AKT is associated with metastasis of nasopharyngeal carcinoma.Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.DA6034 promotes gastric epithelial cell migration and wound-healing through the mTOR pathway.Selective inhibition of EGFR downstream signaling reverses the irradiation-enhanced migration of HNSCC cells.GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.

P2860

Q28074691-A54798BC-7DFB-4F05-B29F-AC3453995392 Q28551853-8C77F14C-C1CA-4E6F-963B-F90D70DEDFAE Q33637161-708C9463-10FA-4B13-A552-AEBD0753BF51 Q34049613-4AF00E1C-5F74-42B7-A193-DAD6F79F537E Q34147649-C3761E8E-ABC0-438C-954F-82C792AB34A7 Q34252978-E3C2F61F-5479-4222-8CF7-19CA491F7E90 Q34389503-E870880B-A311-4938-8D25-3A79CDC9B55B Q34571304-67087EBC-72B0-42C0-A682-01966CEAB2C7 Q35751948-AB6B57F3-B7B3-4BEA-AA9D-BFAD75A1FA94 Q35805039-2A674A59-5EA6-499E-B3BF-7BB4D984D709 Q35955342-07E39345-9F5B-487F-95D5-D2ED53BD1C8A Q35994228-CE71B67F-1EB1-4DBE-AA23-C9835D6A0212 Q36021572-36460A6E-E6CD-46BC-9914-D7BE74FFE5E6 Q36029715-8B0E20C1-D6B4-4801-AC0D-BE546F1DE82A Q36215450-17B299E8-17CB-4E30-BC96-54DECC62A487 Q36653556-63F6EFE7-A8F8-4306-A3BF-DF00A1281900 Q36820341-D6B443DE-2B87-484C-9D55-780188604A68 Q36844399-FF602072-71E6-473C-B600-395412FF935B Q37025086-F0C65901-3541-4378-BB2B-FCE2FF1841A4 Q37060950-985153AA-2F78-48E6-B521-878F850F7CF2 Q37075277-9E953BC6-0FFA-46BE-A984-055519B58157 Q37269265-D56055D3-DE58-473F-B744-A9A4DD12CDF4 Q37362560-C53C3FA3-CDC0-4BBC-AD09-37B1347CC41A Q37492314-5DD4F1EA-9726-4853-A205-E3C450A1DB70 Q37687364-3B6A1B6F-8711-447D-9E0D-8BBD1C71DBCB Q38020381-91622799-7197-44FE-A0D1-F922C3FEF3F0 Q38161944-30063731-595D-4500-8CF8-B171DFAE1DB9 Q38194548-927C3884-0298-481D-AE0D-0CA46F32FDE6 Q38226307-62FEB804-6ACF-40BD-963C-7D7E956D1123 Q38667738-A7C82288-BA9A-425F-BCB3-3B2BB1D14343 Q38752793-CF800824-4B26-4F7F-872D-992A1B6F148B Q38780033-1242ADFA-F3EC-4D9D-9107-4BE1713692E5 Q38945870-FBF7D781-AAC8-4905-90AB-F3C373F23836 Q38957423-BC7B1126-0923-4CEC-827C-CEAB8D8BB016 Q38995499-10ABE4D1-2804-423D-AB35-4DC099F8524C Q39437368-44DE1541-CA5B-42FB-88F4-04C5E2138C26 Q39466612-84E95C4E-BA81-42CE-BBF9-EFDD4B7E4D7E Q39500011-2CAAC5D1-8FAE-44F9-BB32-9BE909A39C56 Q40272583-ABD3B0C3-5941-44AB-AE2A-A233ECFE1DF9 Q41612466-0714673A-E7B3-4640-BA1F-82BFA2A17E90

P2860

EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

http://www.wikidata.org/entity/Q36103054

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy

@ast

EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy

@en

type

label

EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy

@ast

EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy

@en

prefLabel

EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy

@ast

EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy

@en

P1433

Q36103054-3737F1DA-9292-4BBB-BC5C-2F57070921D8

P1476

Q36103054-9FBABA1A-0D4C-4270-B998-7169DFE30059

P2093

Q36103054-03409273-4D76-40EF-BC3E-3F75B5457EA5

Q36103054-1D571286-D949-406F-9D95-3226B1D1F946

Q36103054-4CB4391E-798D-408A-B3F1-26FD81979BEA

Q36103054-C06CBB72-DE02-43D5-BA94-532B77C99D67

Q36103054-C4AD54E2-AAFD-4268-A650-D39796491E6E

Q36103054-D4589F1B-2C5A-4B7C-B285-52E26949F26A

P2860

Q36103054-01C66315-31E4-4194-BCF9-092BFAAF41CE

Q36103054-05DD3BDE-D405-402B-934C-6A63C8281D08

Q36103054-0A1EEF31-7F43-4889-A4CC-5FEAD1D9DD31

Q36103054-0ACC80FA-F586-490E-A28C-EFAFE96D6C54

Q36103054-108FE686-493B-42BF-B5F0-FA2068BC90CB

Q36103054-15FF5D0A-3FFF-44EB-B812-6DD0271E9792

Q36103054-171DE4E2-60AD-4E4F-8FB2-364FE6AD37AB

Q36103054-17C75EC0-874D-49D4-BD10-B05597AF0E01

Q36103054-17E147C9-04BE-42DA-9C1E-EE5257DC2644

Q36103054-1D4E1BC2-58BF-4332-BA4C-2926ACEA2443

P304

Q36103054-6830D434-2A83-4166-96F4-53D4ADF89ACC

P31

Q36103054-288F8F0C-8379-4581-B3AC-826D310C904A

P356

Q36103054-AB8E8B8A-686C-43AA-A8A6-05B5B3B8992D

P407

Q36103054-CA3FA3A9-92DD-40ED-943F-E699916B8E4A

P433

Q36103054-56348690-94FE-4B01-91C6-B4A5B2749488

P478

Q36103054-E13050A8-8196-4720-AD87-A03901267565

P577

Q36103054-ACD32D2B-A3A1-422B-BD6D-BD9CCAECC312

P5875

Q36103054-53D83D81-B4C9-4CC9-BA34-85DB291C4EE2

P698

Q36103054-568BE3D7-53E7-4A62-B719-51D4E3AAFAC1

P932

Q36103054-5C76402C-5DED-4C91-B7F6-CA66AE4E1625

P356

14728222.2011.541440

P1433

Expert Opinion on Therapeutic Targets

P1476

EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy

@en

P2093

Carter Van Waes

http://www.w3.org/2001/XMLSchema#string

Christian Freudlsperger

http://www.w3.org/2001/XMLSchema#string

Jay A Friedman

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Burnett

http://www.w3.org/2001/XMLSchema#string

Vishnu R Kannabiran

http://www.w3.org/2001/XMLSchema#string

Zhong Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

A complex interplay between Akt, TSC2 and the two mTOR complexes

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

Integration of growth factor and nutrient signaling: implications for cancer biology

Current development of mTOR inhibitors as anticancer agents

P304

63-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2011.541440

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49638615

http://www.w3.org/2001/XMLSchema#string

P698

21110697

http://www.w3.org/2001/XMLSchema#string

P932

3399735

http://www.w3.org/2001/XMLSchema#string